Search results for "Kinase inhibition"

showing 3 items of 3 documents

Two maize Kip-related proteins differentially interact with, inhibit and are phosphorylated by cyclin D–cyclin-dependent kinase complexes

2017

Highlight Maize Kip-related proteins can be differentially phosphorylated by different cyclin D–cyclin-dependent kinase complexes and this influences their performance as cyclin-dependent kinase inhibitors.

0106 biological sciences0301 basic medicineCDKsPhysiologyCyclin DPlant Developmental BiologyPlant ScienceZea mays01 natural scienceslaw.inventionCyclins D03 medical and health sciencesGene Expression Regulation PlantCyclin-dependent kinaselawCyclin DPhosphorylationKinase activityKinase inhibitionCyclin-Dependent Kinase Inhibitor ProteinsPlant ProteinsbiologyKinaseKRP phosphorylationfood and beveragesICK/KRPsCyclin-Dependent Kinases030104 developmental biologyZea mays.Biochemistrybiology.proteinCyclin-dependent kinase complexRecombinant DNAPhosphorylationResearch Paper010606 plant biology & botanyCyclin-dependent kinase inhibitor proteinJournal of Experimental Botany
researchProduct

Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.

2017

ABSTRACT Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity. Accordingly, there is a need to target alternative molecules enhancing specific GBM autocrine or paracrine mechanisms and amplifying the effect of standard treatment. Sphingosine 1-phosphate (S1P) is such a lipid target molecule with an important role in cell invasion and proliferation. Sphingosine kinase inhibitors (SKI) prevent S1P formation and induce increased production of reactive oxygen species (ROS), which may potentiate radiation cytotoxicity. We analyzed the effect of SKI singular versus combined treat…

0301 basic medicineCancer ResearchRadiation-Sensitizing AgentsCell SurvivalCellSphingosine kinaseApoptosistemozolomideBiologyRadiation Tolerancesphingosine kinase inhibition03 medical and health scienceschemistry.chemical_compoundCell Line TumorX-raysmedicineHumansGPx1oxidative stressCytotoxicityAutocrine signallingAntineoplastic Agents AlkylatingPharmacologychemistry.chemical_classificationReactive oxygen speciesTemozolomideSphingosineBrain NeoplasmsDrug SynergismChemoradiotherapyMolecular biologyDacarbazinePhosphotransferases (Alcohol Group Acceptor)030104 developmental biologymedicine.anatomical_structureOncologychemistryCell cultureradiosensitivityCancer researchMolecular MedicineDrug Screening Assays AntitumorGlioblastomamedicine.drugResearch PaperCancer biologytherapy
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct